PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 145 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $26,928,000 | +19.8% | 600,010 | -30.9% | 1.19% | +28.7% |
| Q1 2021 | $22,474,000 | +28.5% | 867,724 | 0.0% | 0.93% | +23.7% |
| Q4 2020 | $17,493,000 | +12.6% | 867,724 | +9.2% | 0.75% | -2.7% |
| Q3 2020 | $15,530,000 | +6.7% | 794,369 | -3.6% | 0.77% | -18.0% |
| Q2 2020 | $14,555,000 | +195.4% | 824,169 | +18.1% | 0.94% | +185.7% |
| Q1 2020 | $4,927,000 | +45.9% | 697,899 | +45.7% | 0.33% | +51.6% |
| Q4 2019 | $3,377,000 | -41.3% | 479,074 | 0.0% | 0.22% | -78.0% |
| Q3 2019 | $5,754,000 | +1891.0% | 479,074 | +1904.4% | 0.99% | +2365.0% |
| Q2 2019 | $289,000 | – | 23,901 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
| Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
| RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
| Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
| Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
| Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
| FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
| PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
| FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |